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Abstract We investigated structural requirements for dimerisa-
tion and ligand binding of insulin/IGF receptors. Soluble receptor
fragments consisting of N-terminal domains (L1/CYS/L2, L1/
CYS/L2/F0) or fibronectin domains (F0/F1/F2, F1/F2) were
expressed in CHO cells. Fragments containing F0 or F1 domains
were secreted as disulphide-linked dimers, and those consisting of
L1/CYS/L2 domains as monomers. None of these proteins bound
ligand. However, when a peptide of 16 amino acids from the K-
subunit C-terminus was fused to the C-terminus of L1/CYS/L2,
the monomeric insulin and IGF receptor constructs bound their
respective ligands with affinity only 10-fold lower than native
receptors.
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1. Introduction
The insulin receptor (IR) and type I IGF receptor (IGFR)
are disulphide-linked (KL)2 structures, assembled by dimerisa-
tion and proteolytic cleavage of the respective proreceptors
[1]. Each receptor has a high a⁄nity for its cognate ligand,
and 100^1000-fold lower a⁄nity for the converse ligand [2].
The K-subunit is wholly extracellular and contains the ligand
binding site, while the transmembrane L-subunit signals via its
intracellular tyrosine kinase activity. Attempts to crystallise
the full extracellular portion of these receptors have been un-
successful, but sequence analysis and molecular modelling
predict six distinct structural domains, designated L1, CYS,
L2, F0, F1 and F2 [3]. The L1 and L2 domains are homolo-
gous L-helix structures, linked by disulphide-bonded modules
of the CYS domain, and the F domains are ¢bronectin type
III repeats, each with a 7-stranded L-sandwich structure. The
F1 domain is predicted to have a large (approximately 125
amino acids) inserted loop, containing the site of cleavage
between K- and L-subunits and, in the IR, the sequence en-
coded by alternatively spliced exon 11. A crystal structure has
been solved for a 462 amino acid N-terminal fragment of the
IGFR [4] and the corresponding IR structure is presumably
very similar. The IGFR structure reveals the L1, CYS and L2
domains surrounding a central space of su⁄cient size to ac-
commodate a ligand molecule. However, this IGFR fragment
does not bind IGF-I, and it is uncertain whether the orienta-
tion of domains in the crystal structure is the same as in
native receptor.
It follows from the large size of the receptors relative to
insulin/IGF-I that receptor-ligand contacts must involve only
a small fraction of the receptor surface. Several approaches
have been used to determine the regions of IR and IGFR
which participate directly in ligand binding. Ligand cross-link-
ing suggests that the L1, CYS, L2/F0 and F1 insert regions
are all in close proximity to bound insulin [5^8]. Studies with
IR/IGFR chimeras have shown that the L1 domain of IR and
CYS domain of IGFR make important contributions to spe-
ci¢c, high a⁄nity binding of the cognate ligands [2,9]. Alanine
scanning mutagenesis con¢rmed the importance of the L1
domain for insulin binding [10] and further revealed that con-
served amino acids close to the K-subunit C-terminus (within
the F1 insert) make major contributions to binding of both
insulin and IGF-I [11,12]. It has been suggested that high
a⁄nity ligand binding and receptor activation involve cross-
linking of the two halves of native receptors, by interaction of
distinct faces of a single ligand molecule with di¡erent regions
of the two K-subunits [13,14]. This model o¡ers an explana-
tion for the negative cooperativity of ligand binding, and elec-
tron microscopic images of insulin-receptor complexes are
consistent with it [15]. However, it is not clear which of the
several receptor structural domains implicated in ligand bind-
ing might contribute in cis and which in trans to a cross-linked
complex.
An alternative approach to determining the minimum re-
quirements for receptor assembly and high a⁄nity ligand
binding is to express deletion constructs lacking signi¢cant
portions of the receptor ectodomain. In a C-terminal deletion
series, the smallest IR fragment which bound insulin was the
full-length K-subunit [16]. However, substantial internal dele-
tions (corresponding approximately to what is now recognised
as the F0 domain) within the otherwise full-length, native IR
did not seriously compromise insulin binding [17,18]. More
recently, it was shown that soluble, monomeric K-subunit con-
structs with even larger deletions (residues 469^703) bind in-
sulin with an a⁄nity similar to the full ectodomain [19]. To
investigate further the minimum structural requirements for
high a⁄nity ligand binding, we have studied a number of IR
and IGFR ectodomain fragments with either C-terminal or N-
terminal deletions, and assessed the ability of F0 and F1 insert
sequences to complement binding to other domains.
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2. Materials and methods
2.1. Materials
Insulin was purchased from Sigma and IGF-I was a generous gift
from Ciba-Geigy, Basel. 125I-insulin was a gift from Eli Lilly and 125I-
IGF-I was from Amersham Pharmacia Biotech. Restriction enzymes
and other products used for molecular biology were purchased from
New England Biolabs, Sigma and Stratagene. The human IR and
IGFR cDNAs were gifts from Dr Leland Ellis and Dr Jonathan
Whittaker respectively.
2.2. Construction of cDNAs expressing encoding insulin and
IGF receptor fragments
Receptor constructs and their notations are shown in Fig. 1. Prep-
aration and analysis of plasmid DNA was performed according to
standard methods [20]. All constructs were subject to complete
DNA sequencing to con¢rm that no sequence errors had arisen during
assembly. The wild-type human IR template used to generate the
various constructs contained the exon 11 and the numbering system
used is that of Ebina et al. [21].
The IR593 construct was made by PCR ampli¢cation of nucleotides
1^1998 using the sense primer 5P-GCCGGGCTAGCGCCACCAT-
GGGCACCGGGGGCCGGCGGGGG-3P and antisense primer 5P-
CGGCCTCTAGAGGTGGCATCTGTCTGGACATA-3P. The am-
pli¢ed fragment was digested with NheI and XbaI (sites underlined)
and ligated into the similarly digested vector pcDNA3.1(-)/Myc-His C
(Invitrogen) which had been modi¢ed by insertion of a synthetic oli-
gonucleotide 5P-CTAGACTGGTGCCCCGCGGCTCCAA-3P, encod-
ing a thrombin site (in italics), between its XbaI and HindIII sites.
The IR3Fn construct was made by PCR ampli¢cation of nucleo-
tides 1630^3006 using the sense primer 5P-CAGTGGCCCAGCCGG-
CCGAGTTACTTAAATTTTCTTACATTCGGACATC-3P and anti-
sense primer 5P-AGATGGGCCCGGAGCCGCGGGGCACCAGTT-
TTGCAATATTTGACGGGACGTCTAAATAG-3P (S¢I and ApaI
sites underlined and thrombin site in italics). The IR2Fn construct
was made by PCR ampli¢cation of nucleotides 1996^3006 using the
sense primer 5P-CAGTGGCCCAGCCGGCCACCAACCCCTCTG-
TGCCCCTGGATCCAATC-3P (S¢I site underlined) and the same
antisense primer as for IR3Fn. The IR3Fn and IR2Fn fragments
were digested by S¢I and ApaI and cloned into the similarly digested
vector pSECTag2A (Invitrogen) which provides an N-terminal signal
sequence and C-terminal Myc and His tags.
For constructs IR473, IR473CT, IGFR462 and IR462CT, a modi-
¢ed pBK.CMV vector (pBK.CMV.Myc) was used. A Myc epitope
plus stop codon was introduced by ligating a synthetic oligonucleotide
5P-GATCCGAGCAGAAACATATATCAGAGGAGGACCTAAAC-
TAGGCCGGCG-3P into the BamHI/EcoRI sites of pBK.CMV. The
IR473 construct was made by PCR ampli¢cation of nucleotides 1^
1638 of hIR cDNA using the sense primer 5P-CGAGGGGCTAGC-
CACCATGGGCACCGGGGGCCGGCGGGGG-3P and antisense
primer 5P-GTAAGAGGATCCAAGTAACTCATTTTCACAGGA-
3P. The IGFR462 construct was made by PCR ampli¢cation of nu-
cleotides 1^1521 of hIGFR cDNA using the sense primer 5P-CGA-
GGGGCTAGCCACCATGAAGTCTGGCTCCGGAGGAGGG-3P
and antisense primer 5P-GGTGAAGGATCCGACGTCACTTTCA-
CAGGAGGC-3P. The IR473 and IGFR462 ampli¢ed fragments
were digested with Nhe1 and BamH1 (sites underlined) and cloned
into the similarly digested pBK.CMV.Myc to generate the plasmids
pBK.CMV.IR473 and pBK.CMV.IGFR462.
The IR473CT construct was generated by insertion of a synthetic
oligonucleotide of 54 bp encoding amino acids 704^717 and 730^731
of the hIR, £anked at each end by BamH1 sites (Fig. 1) into the
BamHI site of pBK.CMV.IR473. The BamH1 linkers encode GlySer
sequences at either end of the IRCT sequence. A StuI site was also
introduced within the oligonucleotide to allow identi¢cation of the
recombinant clones, without altering the protein sequence. The same
strategy was used to generate the construct IGFR462CT by inserting
a synthetic oligonucleotide encoding to amino acids 691^706 of
hIGFR in pBK.CMV.IGFR462.
2.3. Cell transfection
CHO cells were grown in Ham’s F12 nutrient mixture (Sigma)
supplemented with 10% new born calf serum (Life Technologies),
100 units/ml penicillin and 100 Wg/ml streptomycin. Cells were seeded
at 20^40% con£uency 24 h prior to transfection of DNA by the Lipo-
fectamine procedure for stable transfection of adherent cells (Life
Technologies). Transfected cells were incubated with selection medium
containing 600 Wg/ml of geneticin (G418; Life Technologies) or 1 mg/
ml of zeocin (Invitrogen) as appropriate for the resistance gene of the
vectors. After 15^20 days, clonal lines were selected by growth at
limiting dilution, expanded and analysed by SDS^PAGE and immu-
noblotting with anti-myc antibody 9E10 [22].
2.4. Ligand binding assays
Wells of microtitre plates (Nunc Immuno1 Modules) were coated
with puri¢ed anti-receptor monoclonal antibodies (10 Wg/ml, 100 Wl/
well) for 16 h at 4‡C. The wells were washed 3 times with binding
bu¡er (75 mM Tris pH 7.8 at 4‡C, 30 mM NaCl, 0.5 mM EDTA, 0.1
mM AEBSF, 10 mM glucose, 0.1% BSA and 0.05% Triton X-100),
blocking bu¡er (1% BSA in binding bu¡er) was added for 4 h at room
temperature, and wells were then washed again. Cell culture media, or
detergent lysates of NIH3T3.HIR3.5 cells expressing wild-type hIR
[23] or IGF-1R/3T3 cells expressing hIGFR [24], were diluted in bind-
ing bu¡er with 200 kU/ml aprotinin and added (100 Wl) to each well
for 16 h at 4‡C. After washing, ligand binding experiments were
performed by adding 125I-insulin (30 000 dpm) or 125I-IGF-I (15 000
dpm) in a ¢nal volume of 100 Wl for 5 h at 4‡C. For competition
studies with unlabelled ligand, the dilution of soluble receptors was
adjusted to give 15% binding of tracer in absence of unlabelled ligand.
The plates were washed with cold binding bu¡er and bound radio-
activity was removed by adding 0.5 M NaOH and Q-counted.
3. Results and discussion
3.1. Expression of receptor fragments
Clonal cell lines expressing the various receptor constructs
with C-terminal Myc epitope tags (Fig. 1) were selected by
immunoblotting cell lysates with anti-Myc antibody. The re-
ceptor proteins were also readily detected in culture media.
Constructs based on N-terminal domains (IR473,
IR473CT, IR593) had apparent molecular masses of 79, 81
and 110 kDa respectively on SDS^PAGE under reducing con-
ditions (Fig. 2A), close to those predicted for the glycosylated
polypeptides. When SDS^PAGE was performed under non-
reducing conditions, the IR593 construct appeared mostly as a
much larger protein of apparent molecular mass approxi-
mately V200 kDa (Fig. 2B), consistent with the formation
of disulphide-linked dimers, and only a very small amount of
monomer was detected. In contrast, the electrophoretic mobi-
lity of the IR473 and IR473CT constructs (also IGFR462 and
IGFR462CT constructs, data not shown) was little altered
Fig. 1. Schematic representation of receptor constructs. Constructs
with the normal receptor N-terminus were named according to the
last C-terminal amino acid, and the presence of an additional 16-
mer peptide from the C-terminal K-subunit C-terminus (CT). Con-
structs with N-terminal truncations were named according to their
number of ¢bronectin type III domains. All constructs included a
C-terminal Myc epitope tag represented with grey box.
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under non-reducing conditions, suggesting that these proteins
are secreted as monomers.
Both constructs with N-terminal deletions (IR3Fn and
IR2Fn) were detected as doublets of apparent Mr 45^50
kDa by anti-Myc blotting following SDS^PAGE under reduc-
ing conditions (Fig. 2A and data not shown). The expected
size of full-length, epitope-tagged IR2Fn is V70 kDa (365
amino acids, seven glycosylation sites) and of IR3Fn V84
kDa (487 amino acids, seven glycosylation sites). The tetraba-
sic sequence which marks the site of cleavage between IR K-
and L-subunits is at residues 732^735 (in F1 insert), and the
fragment corresponding to the tagged extracellular portion of
L-subunit is expected to be approximately 42 kDa (227 amino
acids, four glycosylation sites) as found for receptor expressed
in COS cells [16]. We conclude that both the IR2Fn (F1/F2)
and IR3Fn (F0/F1/F2) proteins are e⁄ciently cleaved at this
position. The appearance of the Myc-tagged L-subunit frag-
ments as doublets under these conditions may re£ect hetero-
geneity of glycosylation. Both the IR2Fn and IR3Fn con-
structs were detected as much larger proteins (apparent Mr
160^200 kDa) following electrophoresis under non-reducing
conditions (Fig. 2B and data not shown), indicative of their
secretion as dimers as for the IR593 protein. As with the
IR593 protein, a trace of IR2Fn monomer was detectable
under non-reducing conditions when blots were overexposed.
In the native receptor the K-subunits are linked by at least
two class I disulphides, one of which involves Cys-524 (in F0
domain) and the other Cys-682/3/5 (in F1 insert), while the K-
and L-subunits are linked by a single class II disulphide be-
tween Cys-647 (in F1) and Cys-872 (in F2) [25^27]. We con-
clude that the presence of either the F0 domain, as in the
IR593 protein, or the F1 domain, as in the IR2Fn protein,
is su⁄cient to promote class I disulphide-linked dimerisation.
Thus the capacity for dimerisation is an intrinsic property of
these domains which is not dependent on the integrity of other
parts of the receptor structure, and in particular does not
require the three N-terminal domains. Moreover, both
IR3Fn and IR2Fn proteins must also contain class II K-L
disulphide links, con¢rming the capacity of the ¢bronectin
domains to fold and assemble independently of the rest of
the receptor.
Native K2L2 receptor heterotetramers will readily dissociate
into KL half-receptors following mild reduction of class I di-
sulphides in vitro [28,29], indicating that non-covalent inter-
actions between half-receptors are not strong. Half-receptors
generated in this way can be induced to reform disulphide-
linked K2L2 heterotetramers by addition of ligand [30^32],
although dimerisation during normal biosynthesis must obvi-
ously occur in the absence of ligand. It is surprising in the
light of these in vitro observations that fragments of the re-
ceptor containing only some of the potential sites of interac-
tion between half-receptors nevertheless assemble biosyntheti-
cally as dimers.
3.2. Ligand binding
The capacity of the various constructs to bind their cognate
Fig. 2. Receptor constructs expressed in CHO cells. Conditioned
medium from clonal cell lines was mixed with Laemmli sample bu¡-
er (with or without DTT) and loaded on 8% SDS^polyacrylamide
gels. A nitrocellulose blot was prepared, probed with anti-Myc anti-
body 9E10, and visualised by enhanced chemiluminescence. Lane 1,
untransfected cells ; lane 2, IR593; lane 3, IR473; lane 4, IR473CT,
lane 5, IR2Fn. Lanes 1a and 4a are overexposed versions of the
corresponding lanes in the main part of the ¢gure. Positions of pre-
stained molecular mass markers (New England Biolabs) are indi-
cated. A: Receptor fragments resolved under reducing conditions
(+DTT). B: Receptor fragments resolved under non-reducing condi-
tions (3DTT).
Fig. 3. Competition assay of 125I-ligand binding to receptor con-
structs. Culture medium from clonal cell lines expressing receptor
constructs, or detergent lysate of cells expressing wild-type receptors
(NIH3T3.HIR3.5 or IGF-1R/3T3), was added to wells coated with
anti-receptor antibody, and incubated with 125I-ligand and varying
concentrations of unlabelled insulin (solid symbols) or IGF-I (open
symbols). Results are expressed as the percentage of 125I-ligand
bound in absence of unlabelled ligand, and data points are the
means of duplicate determinations within a representative experi-
ment. A: IR473CT construct (solid lines) or wild-type IR (dashed
lines) added to wells coated with antibody IR 83-7 and incubated
with 125I-insulin. B: IGFR462CT construct (solid lines) or wild-type
IGFR (dashed lines) added to wells coated with antibody IGFR 16-
13 and incubated with 125I-IGF-I.
Table 1
Speci¢city of ligand binding to receptor constructs





Competition binding assays were performed with IR473CT and
IGFR462CT constructs, or wild-type detergent-solubilised receptors,
as in Fig. 3. IC50 values for each unlabelled ligand are means of
two independent experiments, each conducted in duplicate.
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ligands was assessed in a plate binding assay. Receptor frag-
ments were captured on anti-receptor antibodies which specif-
ically recognise epitopes in the regions 191^290 of IR (Ab 83-
7, used for IR N-terminal fragments), 62^184 of IGFR (Ab
16-13, used for IGFR N-terminal fragments) or 765^770 of IR
(Ab 18-44, used for IRFn constructs) [33^35]. These antibod-
ies do not inhibit ligand binding to soluble receptors. The
antibodies have high a⁄nity for native receptors, but react
very poorly with denatured receptor on blots, indicating
that the epitopes are conformation dependent. It was con-
¢rmed by sequential anti-receptor immunoprecipitation and
anti-Myc blotting that all the expressed receptor fragments
were recognised by appropriate antibodies, and it is therefore
concluded that the fragments assume a native conformation at
least as regards the relevant epitopes.
Binding of 125I-insulin was observed only with the IR473CT
construct. No binding was detected with the IR473, IR593,
IR3Fn or IR2Fn proteins, even when these were tested at 2^
40 times the concentration of IR473CT as normalised by anti-
Myc blotting (data not shown). Similarly, binding of 125I-
IGF-I was detected only with the IGFR462CT construct
and not with IGFR462 (data not shown). These results con-
¢rm previous reports that similar fragments containing just
the ¢rst three domains (L1/CYS/L2) of the IR and IGFR
are unable to bind ligand [4,16]. Moreover the complete
lack of insulin binding to the IR593 construct indicates that
neither dimerisation of the four N-terminal domains nor com-
pletion of the putative contact site between amino acids 390^
488 (exon 6) [7,13] is su⁄cient to create an e¡ective ligand
binding site.
Alanine scanning mutagenesis suggests that amino acids
704^717, close to the C-terminus of the K-subunit, make a
greater energetic contribution to insulin binding than those
in the L1 domain [10,11]. Our data show that this sequence
alone, even in the context of the complete and appropriately
processed F1 domain as in the IR3Fn and IR2Fn constructs,
is not su⁄cient to confer detectable insulin binding at tracer
concentrations. However, the data con¢rm that when the 704^
717 sequence is taken out of its immediate context and fused
to the C-terminus of the L1/CYS/L2 domains, as in IR473CT,
the resulting construct binds insulin very well. Moreover, we
have shown that analogous IGFR constructs behave in the
same way, in that IGFR462 does not bind IGF-I at tracer
concentrations but IGFR462CT binds very well.
The properties of the IR473CT and IGFR462CT proteins
were further studied in competition binding assays with unla-
belled insulin and IGF-I (Fig. 3). Under the conditions of
these assays, with limiting amounts of receptor and tracer
concentrations of radioligand, the concentrations of unla-
belled ligand which inhibit tracer binding by 50% (Table 1)
may be taken as a measure of the Kd. We found that both the
monomeric IR473CT and IGFR462CT constructs have 8^10-
fold lower a⁄nity for their cognate ligands than the native
detergent-solubilised receptors. A⁄nities of the constructs for
heterologous ligand were not so reliably de¢ned, but appear
to be similar to those of the native receptor.
The a⁄nity of IR473CT for insulin was similar to that
reported for isolated half-receptors and free K-subunit
[16,28,29]. Thus the decreased a⁄nity of the IR473CT con-
struct compared to native IR presumably re£ects its mono-
meric structure rather than the absence of speci¢c binding
determinants or the ¢bronectin domains. Half-receptors, like
soluble dimeric ectodomain [36] and native receptors with F0
deletions [17,18] not only show decreased a⁄nity for insulin
but also exhibit linear Scatchard plots indicative of simple
single-site binding. Thus it has been proposed that interac-
tions of ligand with both K-subunits in native receptors are
necessary for highest a⁄nity and negative cooperativity of
ligand binding [13,14]. We have previously shown that insu-
lin/IGF hybrid receptors have even lower a⁄nity for insulin
than isolated half-receptors [37], suggesting that an inappro-
priate trans interaction may be more deleterious to binding
than no interaction at all. The situation with regard to ligand
binding by the IGFR is less clear-cut. It has been reported
that isolated KL half-receptors exhibit decreased a⁄nity rela-
tive to native K2L2 IGFR, similarly to the situation with IR
[38]. However, others have found that binding properties of
IGFR KL and K2L2 were not signi¢cantly di¡erent [39], and
we found that insulin/IGF hybrid receptors bind IGF-I with
similar a⁄nity to wild-type IGFR [37]. In the present studies,
the a⁄nity of monomeric IGFR462CT for IGF-I was clearly
reduced compared to native IGFR. Interestingly, the a⁄nities
for cross-reaction of IGF-I with IR473CT or insulin with
IGFR462CT were very similar to those of the native recep-
tors, suggesting that binding of heterologous ligand does not
depend on receptor dimerisation.
The simplest interpretation of the present data is that bind-
ing determinants in the L1 and C-terminal regions of the IR
K-subunit cooperate in cis to generate an e¡ective binding site,
and that additional trans interactions are provided by some
other portion of the K-subunit in native receptors. It remains
an open question whether a precisely analogous binding
mechanism operates in the IGFR. It is possible that connec-
tion of the C-terminal peptide directly to the L2 domain for-
tuitously mimics the positioning of the same sequence when
present as part of the F1 insert in native receptor. The
IR473CT construct is a little larger than the minimised recep-
tor which has been studied previously [19], having 473 rather
than 468 amino acids of the N-terminal domains, a GlySer
linker between the N-terminal segment and the CT sequence,
and an additional Myc tag at the C-terminus. However, the
two constructs nevertheless appear very similar in their a⁄nity
for insulin. We conclude from this that precise positioning of
the C-terminal sequence relative to the N-terminal portion of
the IR is not essential for insulin binding. It may be that
insulin itself induces an appropriate conformation providing
there is some £exibility in the link between the C-terminal
sequence and the rest of the receptor. It is notable that the
exon 113 form (but not the exon 11+ form) of uncleaved
proreceptor has a greatly reduced a⁄nity for insulin [40],
suggesting that the K-subunit C-terminus is conformationally
constrained in a way which inhibits insulin binding at least in
the absence of exon 11. However, while the exon 11 sequence
of 12 amino acids immediately downstream of the critical C-
terminal contact site enhances insulin binding to uncleaved
proreceptor, the exon 11 sequence exerts a modest negative
in£uence on the a⁄nity of mature IR for insulin, and more
especially for IGF-I [41]. Studies of further constructs involv-
ing fusions of N-terminal domains and C-terminal sequences
of the IR and IGFR K-subunits should further illuminate the
contribution of the C-terminus to the a⁄nity and speci¢city of
ligand binding.
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